Regeneron antibodies in demand after Trump treatment, doctors seek more data | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Thursday
July 24, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
THURSDAY, JULY 24, 2025
Regeneron antibodies in demand after Trump treatment, doctors seek more data

Coronavirus chronicle

Reuters
08 October, 2020, 08:35 am
Last modified: 08 October, 2020, 08:41 am

Related News

  • 98% people developed antibodies after 2nd Covid jab
  • Covid Science: Virus leaves antibodies that may attack healthy tissues
  • Regeneron's Covid antibody drug shows protection for up to 8 months
  • AstraZeneca antibody cocktail succeeds in late-stage study to treat Covid-19
  • Hospitals in ‘red zones’ falling short of beds, doctors

Regeneron antibodies in demand after Trump treatment, doctors seek more data

Medical experts said more data is needed to assess the treatment’s efficacy before wider use should be allowed

Reuters
08 October, 2020, 08:35 am
Last modified: 08 October, 2020, 08:41 am
The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, US September 17, 2020/ Reuters
The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, US September 17, 2020/ Reuters

Patients are asking to join clinical trials of antibody-based Covid-19 drugs after US President Donald Trump was treated last week with an experimental therapy from Regeneron Pharmaceuticals Inc, and on Wednesday he promised to make it free to Americans while touting its benefits.

Medical experts said more data is needed to assess the treatment's efficacy before wider use should be allowed.

Trump was discharged from the hospital late on Monday, just a few days after being diagnosed with Covid-19 that caused enough lung inflammation for blood oxygen levels to fall.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

According to his doctor, blood tests on Monday detected infection-fighting antibodies, which a Regeneron spokesperson said were probably from the treatment.

The company said on Wednesday that it has submitted a request to the US Food and Drug Administration for an emergency use authorization (EUA) for its antibody combination.

Trump says catching Covid-19 was 'blessing from God'

In a video shot outside the White House, Trump credited the Regeneron therapy for his feeling much better than when he was first diagnosed and said he would push for EUAs of that treatment and others like it. He mistakenly said the drug was called Regeneron.

Regeneron's drug is a cocktail of two monoclonal antibodies - manufactured copies of antibodies that are one of the main weapons the immune system generates to fight infections.

The company so far has released some early data pointing to the promise of its therapy for Covid-19, and doctors were concerned Trump's treatment and subsequent promotion could put pressure on regulators

Dr Gary Kleiner, a pediatric immunologist at the University of Miami Miller School of Medicine and investigator in a trial designed to see if Regeneron's antibodies can prevent coronavirus infection, said he has been approached by patients seeking the drug since last week.

Dr Dirk Sostman, head of the research network at Houston Methodist Hospital, a trial site for Regeneron and Eli Lilly & Co antibody programs, said more patients are asking to participate in an antibody trial.

He was cautious about broader use without more data.

"All we have seen are very brief press releases ... so there is not much to go on," he said.

"The politics of the situation would suggest to me that the story could be Trump gets Covid ... then American technology fostered by the Trump Administration cures Covid," Sostman added. "I would think there would be pressure on regulators."

Top US infectious disease expert Dr Anthony Fauci, speaking on Monday on CNN, said he was "strongly suspicious" that Regeneron's drug has contributed to Trump's progress. "Obviously you can't prove that until you do a number of studies to show that it actually works," he said.

Doctors emphasized that the timeline for Trump's illness was not entirely clear. "If he is responding at a pace where he is truly much better, it is going to be due to the antibodies," said Dr Edward Jones-Lopez, infectious disease specialist at the University of Southern California Keck School of Medicine in Los Angeles.

Giving the treatment to the president seems "a tacit endorsement by the federal medical bureaucracy for Regeneron's medicine, and we expect an EUA for the treatment of Covid in a matter of days," Leerink analyst Geoffrey Porges said in a research note.

"Patients most likely to benefit from this treatment have a similar profile to President Trump, in that they had undetectable antibodies at baseline and were early in the course of disease," Regeneron spokeswoman Alexandra Bowie said in an emailed statement.

Regeneron has received $450 million from the US government for up to 300,000 doses of the dual-antibody cocktail, and the company has said those supplies would be distributed free of charge.

Eli Lilly on Wednesday said a mid-stage trial testing its combination antibody therapy showed that it helped cut hospitalization and emergency room visits for Covid-19 patients and that it also planned to seek an EUA.

Shares of Regeneron, up nearly 6% so far this month, closed at $591.69 on Wednesday. Lilly's shares rose 3.4% on Wednesday to close at $148.96.

Top News / World+Biz

Regeneron / Coronavirus Antibodies / Coronavirus treatment

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • 2 Milestone teachers, who died trying to save students, to be given state honour: Govt
    2 Milestone teachers, who died trying to save students, to be given state honour: Govt
  • File photo of Bangladesh Bank. Photo: TBS
    Governor Mansur orders withdrawal of BB dress code
  • Milestone tragedy: Chinese medical experts conduct video consultation with burn institute doctors
    Milestone tragedy: Chinese medical experts conduct video consultation with burn institute doctors

MOST VIEWED

  • Photo: Collected
    Bangladeshi man jailed for life in UK for murdering wife in front of their baby
  • Ctg port authority halts contractor recruitment for Kamalapur ICD operations for two months
    Ctg port authority halts contractor recruitment for Kamalapur ICD operations for two months
  • Fire at Cosmo School in Mirpur on 23 July 2025. Photo: TBS
    Fire breaks out at Cosmo School in Mirpur following generator explosion
  • Representational image. File Photo: Rajib Dhar/TBS
    Debate arises as edu adviser says postponed HSC exams of 22 and 24 July will be held on same day
  • BB issues dress code for all, discourages short-sleeved or length dresses, leggings for female staff
    BB issues dress code for all, discourages short-sleeved or length dresses, leggings for female staff
  • Infographics: TBS
    Stay orders won’t shield defaulters: BB governor 

Related News

  • 98% people developed antibodies after 2nd Covid jab
  • Covid Science: Virus leaves antibodies that may attack healthy tissues
  • Regeneron's Covid antibody drug shows protection for up to 8 months
  • AstraZeneca antibody cocktail succeeds in late-stage study to treat Covid-19
  • Hospitals in ‘red zones’ falling short of beds, doctors

Features

Photo: Collected

24 July: More than 1400 arrested, 3 missing coordinators found

12h | Panorama
Photo: Mehedi Hasan/TBS

Aggrieved nation left with questions as citizens rally to help at burn institute

1d | Panorama
Photo: Mehedi Hasan/TBS

Mourning turns into outrage as Milestone students seek truth and justice

1d | Panorama
Illustration: TBS

Uttara, Jatrabari, Savar and more: The killing fields that ran red with July martyrs’ blood

2d | Panorama

More Videos from TBS

Thai-Cambodian troops clash over disputed border

Thai-Cambodian troops clash over disputed border

45m | TBS World
Former chief justice Khairul Haque detained

Former chief justice Khairul Haque detained

1h | TBS Today
Why are there renewed tensions between Iran and Israel?

Why are there renewed tensions between Iran and Israel?

2h | Others
Coca-Cola is launching a 'Trump version' made with cane sugar

Coca-Cola is launching a 'Trump version' made with cane sugar

4h | Others
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net